Arch Therapeutics Announces Appointment of Guy Fish to the Board
January 04, 2022 09:47 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
December 13, 2021 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
December 01, 2021 07:50 ET
|
Arch Therapeutics, Inc.
Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5® Advanced Wound System FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc....
Arch Therapeutics Launches Experts in Wound Care Program
October 18, 2021 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Launches Coverage and Reimbursement Pilot
October 04, 2021 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer
May 03, 2021 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today...
Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat Series
June 08, 2020 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, today announced that...
UPDATE - Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
October 07, 2019 15:59 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
October 07, 2019 11:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
August 05, 2019 07:50 ET
|
Arch Therapeutics, Inc.
Studies highlight antimicrobial activity for AC5 technology platform; AC5™ Topical Hemostat1 under Review by Notified Body FRAMINGHAM, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics,...